These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2725868)

  • 1. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test.
    Pillon B; Dubois B; Bonnet AM; Esteguy M; Guimaraes J; Vigouret JM; Lhermitte F; Agid Y
    Neurology; 1989 Jun; 39(6):762-8. PubMed ID: 2725868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
    Pillon B; Dubois B; Cusimano G; Bonnet AM; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):201-6. PubMed ID: 2703838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
    Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
    Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels.
    Kulisevsky J; Avila A; Barbanoj M; Antonijoan R; Berthier ML; Gironell A
    Brain; 1996 Dec; 119 ( Pt 6)():2121-32. PubMed ID: 9010015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
    Morrison CE; Borod JC; Brin MF; Hälbig TD; Olanow CW
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1333-41. PubMed ID: 15480842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition memory in Parkinson's disease.
    Flowers KA; Pearce I; Pearce JM
    J Neurol Neurosurg Psychiatry; 1984 Nov; 47(11):1174-81. PubMed ID: 6502175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slowing of high-speed memory scanning in Parkinson's disease is related to the severity of parkinsonian motor symptoms.
    Ransmayr G; Bitschnau W; Schmidhuber-Eiler B; Berger W; Karamat E; Poewe W; Kemmler GW
    J Neural Transm Park Dis Dement Sect; 1990; 2(4):265-75. PubMed ID: 1964055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.
    Rafal RD; Posner MI; Walker JA; Friedrich FJ
    Brain; 1984 Dec; 107 ( Pt 4)():1083-94. PubMed ID: 6509309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease.
    Schubert T; Volkmann J; Müller U; Sturm V; Voges J; Freund HJ; Von Cramon DY
    Exp Brain Res; 2002 May; 144(1):8-16. PubMed ID: 11976755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study of visuospatial discrimination in parkinsonian patients.
    Katsarou Z; Bostantjopoulou S; Alevriadou A; Mentenopoulos G; Avraam X; Kiosseoglou G
    Percept Mot Skills; 1998 Feb; 86(1):171-80. PubMed ID: 9530727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial cognitive profiles in levodopa-induced hypersexuality.
    Harvey NS
    Br J Psychiatry; 1988 Dec; 153():833-6. PubMed ID: 3256388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which factors predict cognitive decline in Parkinson's disease?
    Caparros-Lefebvre D; Pécheux N; Petit V; Duhamel A; Petit H
    J Neurol Neurosurg Psychiatry; 1995 Jan; 58(1):51-5. PubMed ID: 7823067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive slowing in Parkinson's disease resolves after practice.
    Press DZ; Mechanic DJ; Tarsy D; Manoach DS
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):524-8. PubMed ID: 12397144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory for spatial location is affected in Parkinson's disease.
    Pillon B; Ertle S; Deweer B; Sarazin M; Agid Y; Dubois B
    Neuropsychologia; 1996 Jan; 34(1):77-85. PubMed ID: 8852695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
    Cooper JA; Sagar HJ; Doherty SM; Jordan N; Tidswell P; Sullivan EV
    Brain; 1992 Dec; 115 ( Pt 6)():1701-25. PubMed ID: 1486457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression and cognitive impairment in Parkinson's disease.
    Starkstein SE; Preziosi TJ; Berthier ML; Bolduc PL; Mayberg HS; Robinson RG
    Brain; 1989 Oct; 112 ( Pt 5)():1141-53. PubMed ID: 2804609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.
    Gotham AM; Brown RG; Marsden CD
    Brain; 1988 Apr; 111 ( Pt 2)():299-321. PubMed ID: 3378138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.